Segment Information

12 Months Ended

Jun. 30, 2012

Segment Information

Note 8. Segment Information

The Company has one operating segment, the discovery and development of pharmaceutical compounds. The Company’s business contained two geographic segments from inception until MEPL’s legal dissolution in April 2012. The following segment information is net of intercompany transactions.

	Year Ended June 30,
	2012								2011
	USA			Australia		Total			USA			Australia			Total
	(in thousands)								(in thousands)
Statement of Operations:
Income (loss) from operations	$	(8,473	)	$	79	$	(8,394	)	$	(5,016	)	$	(1,435	)	$	(6,451	)
Other income (expense)		871			—		871			(329	)		(1	)		(330	)
Net loss arising during development stage	$	(7,602	)	$	79	$	(7,523	)	$	(5,345	)	$	(1,436	)	$	(6,781	)
Balance Sheet:
Segment assets	$	6,373		$	—	$	6,373		$	4,112		$	56		$	4,168
Segment liabilities	$	(1,774	)	$	—	$	(1,774	)	$	(1,294	)	$	(1,080	)	$	(2,374	)